Markets

Nxera Receives $10 Mln Milestone Payment From AbbVie

June 30, 2026 — 08:25 am EDT

Written by RTTNews.com for RTTNews

(RTTNews) - Nxera Pharma Co., Ltd. (SOLTF) on Tuesday said it received a $10 million milestone payment from AbbVie (ABBV) after achieving a fourth R&D milestone under their multi-target drug discovery collaboration focused on neurological diseases.

The companies partnered in 2022 to discover GPCR-targeting medicines for neurological diseases using Nxera's NxWave platform. The milestone was triggered by the identification of validated and differentiated hit molecules against a neurology target.

With the latest payment, Nxera has received $40 million from AbbVie across four R&D milestones.

Under the agreement, Nxera is also eligible to receive potential option, development and commercial milestone payments totaling up to $1.2 billion, in addition to tiered royalties on global sales.

RTTNews
Founded in the late 1990s by Andrew Mariathasan in New York, with the goal of covering Wall Street for a new generation of investors, RTTNews has expanded steadily over the years to become a trusted provider of content for a wide array of subjects across several platforms. RTT's Financial Newswire is relied upon by some of the world's largest financial institutions, including banks, brokerages, trading platforms and financial exchanges.
More articles by this source

Tags

Markets
Stocks Mentioned
ABBV

Latest Articles
Data is currently not available